Services Revenue Decline and Rising Cloud Costs Cloud Cochlear’s FY25 Outlook

Cochlear Limited posted a 5% increase in sales revenue to $1.17 billion for the half year ended December 2024, driven by strong cochlear and acoustic implant growth despite a decline in Services revenue. The company anticipates FY25 underlying net profit at the lower end of guidance amid increased cloud investments and prepares for new product launches.

  • Sales revenue up 5% to $1,170 million, with cochlear implant revenue rising 13% in constant currency
  • Statutory net profit increased 7% to $205 million; underlying net profit margin steady at 18%
  • Services revenue declined 12% in constant currency, offset by 22% growth in acoustics
  • Interim dividend increased 8% to $2.15 per share, payout ratio at 68%
  • Next-generation cochlear implant and off-the-ear sound processor expected mid-2025 launch
An image related to Cochlear Limited A photo of the logo for Cochlear Add us as a preferred source on Google
Image © middle. Logo © respective owner.

Strong Implant Sales Drive Revenue Growth

Cochlear Limited has delivered a solid first half for the 2025 financial year, reporting a 5% increase in sales revenue to $1.17 billion. This growth was primarily fueled by a 13% rise in cochlear implant revenue on a constant currency basis, alongside a robust 22% increase in acoustics revenue. The company sold 25,390 cochlear implant units, a 5% increase over the prior corresponding period, with notable strength in developed markets such as the US and Asia Pacific.

While adult and senior segments saw approximately 10% growth, the children’s segment experienced a modest decline, reflecting a normalization after strong double-digit growth in the previous half. Emerging markets showed slower unit growth, impacted by lower tender volumes but buoyed by higher-priced private pay segments in China and India.

Services Revenue Decline and Margin Stability

Services revenue, which includes sound processor upgrades, declined 12% in constant currency, following a 29% surge in the first half of 2024. This slowdown is attributed to a deceleration in uptake of the Cochlear™ Nucleus®8 sound processor and cost-of-living pressures delaying replacements, particularly in the US. Despite this, Cochlear maintained an underlying net profit margin of 18%, consistent with its longer-term target, even after factoring in increased cloud computing investments.

Operating expenses rose 10%, driven by expanded R&D and market growth activities, including investments in new product development and market access initiatives. The company’s gross margin held steady at 75%, underscoring operational efficiency amid these investments.

Financial Position and Shareholder Returns

Cochlear’s balance sheet remains robust with net cash of $383 million, despite a $130 million reduction from June 2024, largely due to inventory build-up ahead of upcoming product launches. Capital expenditure of $44 million focused on capacity expansions in Australia and Malaysia. The company declared an interim dividend of $2.15 per share, an 8% increase year-on-year, reflecting confidence in cash flow generation and a payout ratio of 68% of underlying net profit.

Looking Ahead: New Products and Guidance

Looking forward, Cochlear expects underlying net profit for FY25 to be at the lower end of its $410-430 million guidance range. This outlook incorporates a continued decline in Services revenue and higher cloud-related investments, now forecasted at $40 million for FY25. The company is preparing for the commercial release of its next-generation cochlear implant and a new off-the-ear sound processor, the Nucleus® Kanso® 3, anticipated from mid-2025 pending regulatory approvals.

Acoustics growth is expected to remain strong, supported by geographic expansion of the Osia® implant system. Cochlear also plans to continue investing approximately 12% of sales revenue into R&D to sustain long-term growth and competitive positioning. The company’s ongoing operating model redesign and core system upgrades have expanded in scope, with total investments now expected to reach $250 million.

Overall, Cochlear’s half-year results highlight a company balancing solid implant sales growth with strategic investments and evolving market dynamics, setting the stage for a pivotal year ahead.

Get ASX:COH news the moment it breaks

Instant push notifications No waitlist Free
Download on the App Store iPhone & iPad
Get it on Google Play Android
Email alerts

Bottom Line?

Cochlear’s solid implant growth and upcoming product launches promise momentum, but Services revenue softness and rising investments warrant close investor scrutiny.

Questions in the middle?

  • How will the new off-the-ear sound processor impact Services revenue starting FY26?
  • What are the risks and timelines associated with regulatory approvals for the next-generation cochlear implant?
  • How will increased cloud-related investments affect profitability and operational efficiency beyond FY25?